(Q52972998)

10 May 2018

title

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. (English)

1 reference

10 May 2018

1 reference

1 reference

P K Schädlich

1

1 reference

10 May 2018

J G Brecht

series ordinal

2

1 reference

10 May 2018

publication date

1 January 2000

1 reference

10 May 2018

published in

PharmacoEconomics

1 reference

10 May 2018

volume

17

1 reference

10 May 2018

issue

1

1 reference

10 May 2018

page(s)

37-52

1 reference

10 May 2018

Economic outcomes for the treatment of allergic rhinitis

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Effect of air pollution on the prevalence of asthma and allergy: lessons from the German reunification

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Immunotherapy with alginate-conjugated and alum-precipitated grass pollen extracts in patients with allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

International trends in asthma mortality: 1970 to 1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Specific IgE response toward allergenic molecules during perennial hyposensitization: a three-year prospective double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

The future of pharmacoeconomics: a commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

Ragweed immunotherapy in adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200017010-00003

The safety of allergen immunotherapy: a literature review

21 January 2018

1 reference

12 December 2020

Is there a role for immunotherapy in the treatment of asthma? No

1 reference

12 December 2020

The cost of migraine: more than just a headache?

1 reference

12 December 2020

Is there a role for immunotherapy in the treatment of asthma? Yes

1 reference

12 December 2020

Pollinosis. II. Specific hyposensitization: indications and results of treatment. A study with the allergen preparation Stallergenes-Depot in the pollen season of 1976, 1977 and 1978

1 reference

12 December 2020

Booster immunotherapy (BIT)

1 reference

12 December 2020

Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Late results of hyposensitization therapy of pollinosis. Follow-up studies of 328 cases 2-5 years after termination of injection treatment with aqueous or semi-depot allergen extracts

1 reference

12 December 2020

Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study

1 reference

12 December 2020

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results

1 reference

12 December 2020

Prognosis in adult asthma: a national study

1 reference

12 December 2020

Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis

1 reference

12 December 2020

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

12 December 2020

Cost-of-illness studies: a major headache?

1 reference

12 December 2020

Recommendations for hyposensitization with allergen extracts. Medical Society of German Allergologists

1 reference

12 December 2020

A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects

1 reference

12 December 2020

Observations on the treatment of seasonal rhinitis with chemically modified pollen allergen

1 reference

12 December 2020

Position paper: Immunotherapy

1 reference

12 December 2020

A prospective study of the natural history of asthma. Remission and relapse rates

1 reference

12 December 2020

The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study

1 reference

12 December 2020

A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine

1 reference

12 December 2020

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

1 reference

12 December 2020

Epidemiology of hay fever and perennial allergic rhinitis

1 reference

12 December 2020

[Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies]

1 reference

12 December 2020

10.2165/00019053-200017010-00003

Identifiers

DOI

1 reference

10 May 2018

Dimensions Publication ID

1013998267

0 references

1 reference

10 May 2018